Trial Profile

A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sargramostim (Primary) ; Sargramostim (Primary)
Indications Acute hypoxia; COVID 2019 infections; Hypoxaemia; Respiratory insufficiency
Focus Therapeutic Use
Acronyms SARPAC

01 Mar 2021 Status changed from active, no longer recruiting to completed.
26 Feb 2021 According to a Partner Therapeutics Media Release, the full study and translational results are being prepared for publication.
26 Feb 2021 Results published in the Partner Therapeutics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com